期刊
BIOMARKERS IN BRAIN DISEASE
卷 1180, 期 -, 页码 75-96出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2009.04945.x
关键词
Alzheimer's; biomarkers; genetics
资金
- National Institute on Aging of the National Institutes of Health [P01AG07232, R37AG15473, P50 AG08702]
- Alzheimer Association
- Blanchette Hooker Rockefeller Fund
- Banbury Fund
- Merrill Lynch Foundation
- NATIONAL INSTITUTE ON AGING [R37AG015473, P50AG008702, P01AG007232, K23AG034550] Funding Source: NIH RePORTER
Late-onset Alzheimer's disease (LOAD) is the most common cause of late-onset dementia in western societies. Despite remarkable achievements in human genetics throughout the years, in particular technological advances in gene mapping and in statistical methods that relate genetic variants to disease, to date only a small proportion of the genetic contribution to LOAD can be explained leaving several remaining genetic risk factors to be identified. A possible explanation for the difficulty in gene identification is that LOAD is a multifactorial complex disorder with both genetic and environmental components. Multiple genes with small effects each (quantitative trait loci [QTLs]) are likely to contribute to the quantitative traits associated with the disease, such as memory performance, amyloid/tau pathology, or hippocampal atrophy. The motivation for identifying the genetics of LOAD is clear. Not only could it shed light on disease pathogenesis, but it may also provide potential targets for effective treatment, screening, and prevention. Here, we review the usefulness of genetic variation as diagnostic tools and biomarkers in LOAD and discuss the potentials and difficulties researchers face in designing appropriate studies for gene discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据